Clinical Trial Search

Primary: Percent of Participants With Central Nervous System (CNS) Progression Free Survival (PFS) — 88.9 percentage of participants

Primary: Progression Free Survival (irPFS) — 21; 1; 3; 1 Participants

Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants

Primary: The Number of Participants With Central Nervous System (CNS) Best Overall Response — 0; 0; 6; 9 Participants

Primary: Clinical Benefit Rate (CBR) — 0.1 proportion of patients with CBR

Primary: Complete Response (CR) Rate in the Brain at 12 Weeks Post-radiation Therapy (RT) Using the RECIST 1.1 Criteria Based on Brain Magnetic Resonance Imaging (MRI) — 5.8; 0…

Primary: Central Nervous System (CNS) Objective Response Rate — 63 percentage of participants

Primary: Number of Participants With Adverse Events — 0 Participants

Primary: Proportion of Patients Dying of Neurological Death, Defined as Dying With Progressive Neurological Dysfunction Regardless of Systemic Disease Status — 5 patients

Primary: Central Nervous System (CNS) Progression-free Survival(PFS) — 12; 2 participants

Primary: Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide — 42.8 percentage of patients with response

Primary: Number of Patients With Objective Treatment Response (Complete or Partial) in the CNS — 2 Participants

Primary: Overall Response Rate (ORR) — 21 Participants

Primary: Local Control — 13; 23; 2; 1 participants

Primary: Overall Response Rate — 71 % of pts w/complete or partial response

Primary: The Average Time From HBO Chamber Exit to SRS beam-on — 8.3 minutes

Primary: The Maximum Tolerated Dose of Lapatinib When Combined With Cranial Radiation in Patients With CNS Metastases From HER2-positive Breast Cancer. — 1250 milligrams

Primary: CNS Objective Response Rate (ORR) — 5; 14; 0 percentage of participants

Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume

Primary: Objective Response Rates. Assessed With Cranial MRI — 78.6; 48.1 Percentage of participants with OR — p=0.019

Primary: Objective Response Rate Per Composite Response Criteria — 7.5; 48.6; 33.3 percent of participants

Primary: Neurocognitive Progression as Measured by the Number of Participants With Cognitive Deterioration by 3 Months — 40; 44 Participants — p=<0.001

Primary: Progression-free Survival (Phase II) — 23.0; 19.5 months — p=0.36

Primary: Number of Patients With Intracranial Response — 3 participants

Primary: Maximum Tolerated Dose (MTD) of Hypofractionated Radiosurgery Defined as the Highest Dose Level Where a Grade 3 or Greater With an Attribution Score of ≥ 3 Develops in ≤…

Primary: Radiographic Response Assessed by Macdonald Criteria Every 2 Months — 3; 2; 4; 3 participants

Primary: Local Control Rate (LCR) at 6 Months — 0.817 proportion of patients

Primary: Survival Free of Neurological Progression, Measured in Weeks — 6 weeks

Primary: Overall Survival — 4.0; 3.6 months — p=0.1862

Primary: 1-year Survival Rate — 31.8 Percentage of patients alive at 1 year